{"entity":{"id":"rejuv-life-money-after-treatment","kind":"technology","name":"Money after treatment: what the cost of cancer does once the treatment has finished","aka":[],"tldr":"In a United States cohort covering 231,596 people diagnosed between 1995 and 2009, those who filed for bankruptcy after a cancer diagnosis had a mortality hazard ratio of 1.79 against propensity-matched people who did not. In a national survey of people over 50, 42.4 per cent had depleted their entire assets two years after diagnosis, losing an average of 92,098 dollars.","summary":"The corpus already carries financial toxicity as a term and financial navigation as a technology, and this record is the part they do not cover: what happens to money after active treatment ends, when the income has gone and the costs have not.\n\nThe American evidence is the strongest because the data linkage exists there. A retrospective cohort linked medical, personal, legal and bankruptcy records in the Western District of Washington for 1995 to 2009 and found that people with cancer were 2.65 times more likely to file for bankruptcy than people without. Younger patients had rates two to five times higher than patients aged 65 or over, which the authors read as Medicare and Social Security cushioning the older group.\n\nThe follow-up asked whether that mattered to survival. Western Washington registry records for 231,596 people diagnosed between 1995 and 2009 were linked to federal bankruptcy records; 4,728 filed. After propensity matching on demographics and clinical factors, 3,841 remained in each group, with a mean age of 53, mean income of 49,000 dollars, 84 per cent with local or regional stage disease and similar initial treatment in both groups. The adjusted hazard ratio for mortality in those who filed was 1.79 (95 per cent confidence interval 1.64 to 1.96), with the highest ratios in colorectal, prostate and thyroid cancers, and excluding distant-stage disease did not change the result. The authors are careful about what that means: severe financial distress \"appears to be a risk factor for mortality\", and \"Further research is needed to understand the process by which extreme financial distress influences survival\". An association in matched observational data is not a demonstration that bankruptcy kills people; it is a strong signal that the two travel together and a reason to treat money trouble as a clinical finding.\n\nThe third dataset covers assets rather than bankruptcy. A longitudinal analysis of a national survey of Americans over 50 covered an estimated 9.5 million new cancer diagnoses between 2000 and 2012, using the two years before diagnosis as a historical control. Two years after diagnosis, 42.4 per cent had depleted their entire life's assets, with average losses of 92,098 dollars; at four years, 38.2 per cent remained in that position. Higher odds went with worsening cancer, a requirement for continuing treatment, being female, Medicaid or no insurance, being retired, increasing age, income and household size, and several clinical characteristics.\n\nWhy the mechanism differs by country, and why the numbers do not transfer. In a system where treatment is billed, the damage is done by bills, co-payments, insurance design and the loss of employer-provided cover when a job ends. In a tax-funded system the treatment is free at the point of use and the damage is done by the same loss of income, plus travel to appointments, hospital parking, heating a house that is now occupied all day, childcare, new clothes for a changed body, and prescription and dental charges where they apply. The European review cited on the right-to-be-forgotten record found objective financial burden in 41 to 48 per cent and subjective strain in 7 to 39 per cent of people with cancer \"even in public health care systems\", which is the best available indication that the problem is not confined to one financing model. OnCo did not verify a United Kingdom figure from a primary source in this round and therefore prints none; the charity helplines that produce those estimates are also the route to a free benefits check, which is the useful action rather than the number.\n\nWhat can be done, graded honestly. Financial navigation, meaning a trained person who screens for money problems and connects patients to assistance, insurance review and legal help, has its own record in the corpus. The European review's assessment of its evidence is the one to hold: \"Eleven trials of early financial navigation produced only modest, short-term improvements.\" That is a real effect and a small one, and it is still better than the alternative of nobody asking. Screening for financial hardship at diagnosis, treating it as a measured side effect rather than a private misfortune, is the subject of several proposals already in this corpus.\n\nThe practical sequence for a reader, which is the same in both systems and is almost never given at the right time: have the benefits conversation in the first month rather than the third, because entitlements are not backdated far and because the paperwork takes weeks; ask about travel costs, which are reimbursable in several systems and almost never claimed; and tell the team, because a treatment plan that a person cannot afford to attend is not a treatment plan.","status":"established","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Financial_toxicity","links":[{"label":"Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis (Health Aff 2013)","url":"https://doi.org/10.1377/hlthaff.2012.1263"},{"label":"Financial insolvency as a risk factor for early mortality among patients with cancer (JCO 2016)","url":"https://doi.org/10.1200/JCO.2015.64.6620"},{"label":"Death or debt? National estimates of financial toxicity in persons with newly-diagnosed cancer (Am J Med 2018)","url":"https://doi.org/10.1016/j.amjmed.2018.05.020"},{"label":"Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons (ESMO Open 2025)","url":"https://doi.org/10.1016/j.esmoop.2025.105767"}],"tags":["rejuvenation","survivorship","evidence:moderate","psychosocial","equity"],"related":["idea-moon-financial-toxicity-screening","idea-cost-financial-toxicity-screening","idea-reg-financial-toxicity-vital-sign","idea-acc-financial-toxicity-screening-at-diagnosis"],"cancers":["colorectal","prostate","thyroid","breast-hr-positive","multiple-myeloma","nsclc"],"sections":["rejuvenation","supportive-care"],"technologies":["financial-navigation","rejuv-life-return-to-work","rejuv-life-employment-rights-uk","rejuv-life-employment-rights-us","rejuv-life-insurance-loans-and-the-right-to-be-forgotten","rejuv-mind-distress-screening","survivorship-care-plan"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["financial-toxicity","work-and-money-breast-cancer-uk","quality-of-life"],"trials":[],"people":[],"bottlenecks":["b-survivorship","b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Financial harm from cancer compounds. Lost income reduces the capacity to absorb a shock at the moment the shock arrives, and the responses available to a household under pressure, drawing down savings, missing payments, skipping medication and delaying follow-up, each raise the probability of the next problem. That is the proposed mechanism linking severe financial distress to worse survival, and it is why the intervention point is early rather than at the point of insolvency.","strengths":["Registry-linked bankruptcy data on 231,596 people rather than survey self-report","Asset depletion measured longitudinally with a pre-diagnosis control period","Screening and navigation exist, are cheap, and have randomised evidence even if the effect is modest"],"limitations":["The bankruptcy and asset data are American and do not transfer to tax-funded systems","The mortality association is observational, and the authors say the mechanism is not established","Financial navigation trials show only modest, short-term improvements"]},"route":"/technologies/rejuv-life-money-after-treatment/","neighbours":{"idea":[{"id":"idea-reg-financial-toxicity-vital-sign","kind":"idea","name":"Screen every cancer patient for financial toxicity as a vital sign, with navigation","route":"/ideas/idea-reg-financial-toxicity-vital-sign/"},{"id":"idea-acc-financial-toxicity-screening-at-diagnosis","kind":"idea","name":"Screen every patient for financial hardship at diagnosis and connect them to help","route":"/ideas/idea-acc-financial-toxicity-screening-at-diagnosis/"},{"id":"idea-moon-financial-toxicity-screening","kind":"idea","name":"Screen every patient for financial toxicity at diagnosis and refer like any other symptom","route":"/ideas/idea-moon-financial-toxicity-screening/"},{"id":"idea-cost-financial-toxicity-screening","kind":"idea","name":"Screen every patient for money trouble the way we screen for pain","route":"/ideas/idea-cost-financial-toxicity-screening/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"technology":[{"id":"rejuv-life-employment-rights-uk","kind":"technology","name":"Employment rights with cancer in the United Kingdom","route":"/technologies/rejuv-life-employment-rights-uk/"},{"id":"rejuv-life-employment-rights-us","kind":"technology","name":"Employment rights with cancer in the United States","route":"/technologies/rejuv-life-employment-rights-us/"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/"},{"id":"rejuv-life-return-to-work","kind":"technology","name":"Going back to work after cancer: the rates, and the programmes that change them","route":"/technologies/rejuv-life-return-to-work/"},{"id":"rejuv-life-insurance-loans-and-the-right-to-be-forgotten","kind":"technology","name":"Insurance, mortgages and the right to be forgotten","route":"/technologies/rejuv-life-insurance-loans-and-the-right-to-be-forgotten/"},{"id":"rejuv-mind-distress-screening","kind":"technology","name":"Screening for distress: what the thermometer can and cannot do","route":"/technologies/rejuv-mind-distress-screening/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"},{"id":"rejuv-access-what-it-costs-elsewhere","kind":"technology","name":"What recovery costs in the rest of the world","route":"/technologies/rejuv-access-what-it-costs-elsewhere/"},{"id":"rejuv-access-what-it-costs-uk","kind":"technology","name":"What recovery costs in the UK, and what it does not","route":"/technologies/rejuv-access-what-it-costs-uk/"},{"id":"rejuv-access-what-it-costs-us","kind":"technology","name":"What recovery costs in the United States","route":"/technologies/rejuv-access-what-it-costs-us/"}],"term":[{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/"},{"id":"work-and-money-breast-cancer-uk","kind":"term","name":"Work and money during breast cancer treatment (UK)","route":"/terms/work-and-money-breast-cancer-uk/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}],"trial":[{"id":"rejuv-trial-canwork","kind":"trial","name":"CanWork: an occupational therapy programme to help women return to work after breast cancer","route":"/trials/rejuv-trial-canwork/"}]}}